Skip to content
The Policy VaultThe Policy Vault

Otrexup — Blue Cross Blue Shield of Kansas

severe, recalcitrant, disabling psoriasis

Preferred products

  • RediTrex

Initial criteria

  • Member must have had an insufficient therapeutic response to or are intolerant of an adequate trial of first-line therapy including full dose non-steroidal anti-inflammatory agents (NSAIDs).
  • For rheumatoid arthritis (RA) or polyarticular juvenile idiopathic arthritis (pJIA), the diagnosis must meet ACR criteria.
  • For psoriasis, diagnosis must be established, as by biopsy and/or after dermatologic consultation.